country,alpha_2_code,alpha_3_code,numeric_code,indicator,time_period,obs_value,sex,unit_multiplier,unit_of_measure,observation_status,observation_confidentaility,time_period_activity_related_to_when_the_data_are_collected,current_age
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,4,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,2,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,1,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,5,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,8,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,7,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,8,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,16,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,16,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,21,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,21,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,30,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,24,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,21,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,34,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,32,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,27,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,42,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,21,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,19,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,33,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,39,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,46,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,49,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,34,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,24,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,27,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,27,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,15,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,10,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,12,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,22,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,33,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,31,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,28,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,27,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,37,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,59,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,66,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,75,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,80,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,89,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,62,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,47,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,41,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,56,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,71,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,65,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,70,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,64,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,82,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,87,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,83,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,83,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,85,Total,Units,%,Estimated value,Free,,Total
Armenia,AM,ARM,51,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,12,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,22,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,27,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,40,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,57,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,66,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,85,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,94,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,75,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,80,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,67,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,61,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,68,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,23,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,10,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,18,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,19,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,25,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,20,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,20,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,22,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,31,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,24,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,15,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,32,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,18,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,28,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,75,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,93,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,92,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,64,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,79,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,78,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,57,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,66,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,77,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,71,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,82,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,84,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,84,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,81,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,13,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,17,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,19,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,18,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,33,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,71,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,79,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,71,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,79,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,95,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,91,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,27,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,34,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,50,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,42,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,45,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,55,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,65,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,89,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,84,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,86,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,74,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,83,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,86,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,89,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,75,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,68,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,86,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,88,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,82,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,86,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,86,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,32,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,36,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,38,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,41,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,54,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,39,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,44,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,50,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,56,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,63,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,70,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,79,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,83,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,71,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,59,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,62,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,66,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,75,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,87,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,94,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,76,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,76,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,67,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,67,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,94,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,35,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,46,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,50,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,57,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,65,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,75,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,77,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,88,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,83,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,79,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,86,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,72,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,85,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,17,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,20,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,28,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,46,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,65,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,50,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,48,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,53,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,63,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,71,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,71,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,72,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,64,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,70,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,11,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,24,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,19,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,25,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,20,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,19,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,11,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,12,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,8,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,8,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,14,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,25,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,24,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,34,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,43,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,52,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,90,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,91,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,83,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,83,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,48,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,77,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,72,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,64,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,55,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,84,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,77,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,80,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,93,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,48,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,46,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,60,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,76,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,88,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,91,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,89,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,93,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,92,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,86,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,81,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,91,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,84,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,8,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,12,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,13,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,31,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,50,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,59,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,63,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,57,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,46,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,60,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,51,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,46,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,41,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,40,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,16,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,22,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,21,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,18,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,38,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,50,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,60,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,39,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,42,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,38,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,49,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,48,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,24,Total,Units,%,Estimated value,Free,,Total
Djibouti,DJ,DJI,262,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,36,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,31,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,44,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,55,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,42,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,48,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,41,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,42,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,38,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,36,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,31,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,25,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,42,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,55,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,40,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,42,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,46,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,46,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,48,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,49,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,51,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,51,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,51,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,79,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,60,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,74,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,85,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,76,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,8,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,5,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,5,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,18,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,13,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,12,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,19,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,17,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,17,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,19,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,20,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,31,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,30,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,19,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,38,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,45,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,65,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,74,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,71,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,70,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,67,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,69,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,60,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,69,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,61,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,78,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,80,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,81,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,30,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,49,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,85,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,94,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,92,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,70,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,79,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,91,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,79,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,89,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,74,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,83,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,68,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,78,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,88,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,90,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,93,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,28,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,43,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,68,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,80,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,82,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,90,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,81,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,78,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,90,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,92,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,36,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,62,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,66,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,32,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,46,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,34,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,57,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,82,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,75,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,38,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,53,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,46,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,41,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,35,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,20,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,26,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,34,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,43,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,44,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,54,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,68,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,63,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,69,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,74,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,89,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,70,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,75,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,67,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,46,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,62,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,53,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,55,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,55,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,67,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,59,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,58,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,57,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,52,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,50,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,67,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,65,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,71,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,>95,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,>95,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,75,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,94,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,82,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,91,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,65,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,87,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,81,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,72,Total,Units,%,Estimated value,Free,,Total
Georgia,GE,GEO,268,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,64,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,39,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,54,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,59,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,48,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,56,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,52,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,67,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,76,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,81,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,84,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,82,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,87,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,88,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,90,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,24,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,31,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,23,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,36,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,31,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,19,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,24,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,25,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,31,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,31,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,31,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,34,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,38,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,38,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,18,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,33,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,33,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,66,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,53,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,59,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,62,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,57,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,69,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,17,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,24,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,37,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,60,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,87,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,85,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,85,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,64,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,77,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,79,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,59,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,60,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,59,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,42,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,53,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,56,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,72,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,57,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,62,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,58,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,46,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,54,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,61,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,47,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,66,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,81,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,65,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,46,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,76,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,89,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,86,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,79,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,85,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,91,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,94,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,77,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,72,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,65,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,63,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,39,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,41,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,46,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,44,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,46,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,42,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,45,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,48,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,57,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,46,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,40,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,45,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,45,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,55,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,3,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,2,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,3,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,5,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,7,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,9,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,11,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,14,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,17,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,19,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,18,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,16,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,19,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,17,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,14,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,18,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,28,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,30,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,38,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,29,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,39,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,42,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,49,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,48,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,48,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,44,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,40,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,32,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,57,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,47,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,48,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,50,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,71,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,82,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,83,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,86,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,86,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,89,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,73,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,86,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,88,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,90,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,46,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,63,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,52,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,54,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,63,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,81,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,83,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,77,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,86,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,94,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,90,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,90,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,82,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,89,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,46,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,33,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,58,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,62,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,67,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,48,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,60,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,63,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,65,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,63,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,83,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,81,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,90,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,90,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,13,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,23,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,23,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,25,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,14,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,16,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,35,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,35,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,41,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,30,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,35,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,46,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,54,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,63,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,67,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,92,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,93,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,90,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,94,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,77,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,87,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,86,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,90,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,87,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,90,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,93,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,21,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,31,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,32,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,26,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,27,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,53,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,64,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,74,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,87,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,89,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,67,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,94,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,85,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,63,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,62,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,75,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,76,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,76,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,76,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,79,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,78,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,2,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,11,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,8,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,6,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,5,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,4,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,2,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,8,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,18,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,20,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,14,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,19,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,19,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,27,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,26,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,48,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,58,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,66,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,70,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,80,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,86,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,92,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,95,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,91,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,71,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,73,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,72,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,64,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,69,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,74,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,36,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,50,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,54,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,32,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,35,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,40,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,36,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,36,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,38,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,30,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,31,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,38,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,34,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,33,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,11,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,11,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,6,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,12,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,79,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,75,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,24,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,17,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,28,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,50,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,29,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,11,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,34,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,46,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,57,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,60,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,84,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,88,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,85,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,90,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,86,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,80,Total,Units,%,Estimated value,Free,,Total
Mauritius,MU,MUS,480,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,79,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,21,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,44,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,68,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,72,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,81,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,82,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,76,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,84,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,85,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,86,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,82,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,86,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,90,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,90,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,42,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,50,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,58,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,61,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,71,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,75,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,82,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,83,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,87,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,87,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,83,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,22,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,44,Total,Units,%,Estimated value,Free,,Total
Myanmar,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,56,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,55,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,60,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,53,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,67,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,78,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,85,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,90,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,92,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,15,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,23,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,29,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,35,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,43,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,41,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,55,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,62,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,51,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,46,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,48,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,73,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,80,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,77,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,61,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,84,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,80,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,81,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,87,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,83,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,83,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,89,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,95,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,80,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,82,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,64,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,57,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,57,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,69,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,46,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,74,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,47,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,44,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,37,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,30,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,29,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,35,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,45,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,25,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,30,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,35,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,47,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,55,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,48,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,51,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,46,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,41,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,41,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,37,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,35,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,34,Total,Units,%,Estimated value,Free,,Total
Nigeria,NG,NGA,566,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,33,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,3,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,6,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,3,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,9,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,4,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,11,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,6,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,8,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,14,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,17,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,5,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,17,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,11,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,11,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,67,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,76,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,74,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,85,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,72,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,78,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,71,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,75,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,69,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,61,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,59,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,79,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,79,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,88,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,5,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,14,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,21,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,28,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,34,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,28,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,32,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,39,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,49,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,62,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,46,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,51,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,51,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,58,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,63,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,78,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,69,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,62,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,69,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,56,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,65,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,67,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,66,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,80,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,66,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,69,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,65,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,63,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,9,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,12,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,11,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,7,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,9,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,11,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,13,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,14,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,15,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,19,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,19,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,11,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,6,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,8,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,52,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,52,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,59,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,61,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,64,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,73,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,81,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,80,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,70,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,87,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,71,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,84,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,89,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,88,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,78,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,>95,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,89,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,92,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,85,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,82,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,70,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,77,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,86,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,87,Total,Units,%,Estimated value,Free,,Total
Romania,RO,ROU,642,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,81,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,68,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,94,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,31,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,38,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,46,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,68,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,60,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,77,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,82,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,77,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,90,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,94,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,93,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,94,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,34,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,43,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,55,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,50,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,48,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,60,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,61,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,68,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,76,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,71,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,68,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,84,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,73,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,87,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,<1,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,3,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,6,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,3,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,5,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,12,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,13,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,15,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,20,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,24,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,25,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,23,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,56,Total,Units,%,Estimated value,Free,,Total
Somalia,SO,SOM,706,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,47,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,90,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,94,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,8,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,11,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,12,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,22,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,20,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,47,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,33,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,71,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,81,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,67,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,69,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,66,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,66,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,76,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,5,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,5,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,6,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,4,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,6,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,6,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,5,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,7,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,5,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,3,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,3,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,2,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,6,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,3,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,56,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,83,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,82,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,80,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,84,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,92,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,79,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,70,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,68,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,64,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,70,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,66,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,65,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,61,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,14,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,21,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,29,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,36,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,53,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,56,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,61,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,59,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,85,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,74,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,87,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,89,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Tajikistan,TJ,TJK,762,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,94,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,94,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,94,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,94,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,32,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,67,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,74,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,77,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,80,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,85,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,91,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,74,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,84,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,86,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,75,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,77,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,82,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,85,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,10,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,12,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,11,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,14,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,31,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,19,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,13,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,12,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,12,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,17,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,26,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,28,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,34,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,18,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,38,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,63,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,69,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,74,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,75,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,81,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,83,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,81,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,83,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,87,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,94,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Ukraine,UA,UKR,804,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,60,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,77,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,91,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,88,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,94,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,94,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,>95,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,68,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,77,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,81,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,80,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,85,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,73,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,84,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,68,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,78,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,62,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,64,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,64,Total,Units,%,Estimated value,Free,,Total
Uruguay,UY,URY,858,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,71,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,10,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,20,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,77,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,78,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,77,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,82,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,81,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,61,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,69,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,70,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,66,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,74,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,75,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,78,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,7,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,8,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,11,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,14,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,18,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,19,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,20,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,17,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,19,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,14,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,18,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,23,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,38,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,36,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,50,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,42,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,43,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,39,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,54,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,53,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,66,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,73,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,85,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,87,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,89,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,79,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,74,Total,Units,%,Estimated value,Free,,Total
Vietnam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,80,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,5,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,2,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,3,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,4,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,3,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,2,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,2,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,2,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,4,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,2,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,4,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,14,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,14,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,69,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,72,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,77,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,86,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,92,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,85,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,88,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,93,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,87,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,91,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,92,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,90,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,88,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,90,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,29,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,48,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,74,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,73,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,80,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,80,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,85,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,89,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,91,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,92,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,87,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,85,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,84,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2023,88,Total,Units,%,Estimated value,Free,,Total
